Xortx Therapeutics (TSE:XRTX) has released an update.
Xortx Therapeutics has released its financial statements for the first quarter of 2024, showing a total asset increase to $6.05 million from the end of the previous year. However, the company also reported an increase in total liabilities to $3.56 million and a comprehensive loss, including research and development expenses, totaling over $1.08 million before other items. This report highlights the financial movements and challenges faced by the company as it navigates through the fiscal year.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
